Arcus Biosciences Inc. (RCUS) — RQD Stock Rating Cockpit

The Roarable RQD rating assigns a score of 19 out of 100, graded E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). Each of the five pillars scores 3 to 5 out of 20 (per the Roarable RQD rating):

• Fundamental Cash Engine (4/20): The rating cites ROIC of -35% and FCF yield of -20.42%. For a prospective investor, this indicates the business is currently consuming cash rather than generating it relative to its market value. Upside from this pillar would require a material operating turnaround that the source data does not show.
• Whale 13F Flow (4/20): The rating scores institutional accumulation and options positioning at 4/20. The source data contains no 13F holder records (see Analyst View section), so the basis for this score cannot be independently verified here.
• Insider Conviction (3/20): The rating scores SEC Form 4 and Congressional PTR cluster flow at 3/20, indicating weak insider signaling. No insider transactions are itemized in the source data.
• Macro Regime Fit (3/20): Beta is 1.0 and the rating notes sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market; the low score reflects weak alignment with the current regime as assessed by the rating.
• Forensic Balance Sheet (5/20): Altman Z-Score is 2.5, Piotroski F-Score is 1/9, and Debt/Equity is 0.5 (per the Roarable RQD rating). The weak Piotroski reading signals poor fundamental quality across multiple checks, and the Altman figure sits in a zone that warrants caution about financial distress risk.

Implications for a prospective investor: The aggregate picture is one of negative cash generation, weak insider and institutional conviction, and low forensic quality. The main upside argument is the price's position relative to its 52-week range and recent news flow around clinical data, but the rating's scoring does not support that as a fundamental driver. Any valuation case requires a view on future cash generation that the current source data does not establish. This is educational analysis, not personalized advice.

Per the SEC financials, the company reported losses at the operating and net levels in each period shown, with operating margin at -60% and net margin at -60% (per the market data). Gross margin is reported as 0%. ROIC is -35% (per the market data). Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. Cash rose from $150.0M to $222.0M between FY 2024 and FY 2025 while FCF was negative in every period, so balance sheet liquidity depends on continued external funding sources the source data does not describe.

Per the recent news feed, the most-cited catalyst is kidney-cancer clinical data, with headlines referencing "Casdatifan ARC-20" data (per the news feed). Multiple headlines describe a stock offering and a roughly 20% decline in shares, alongside a later report of a surge on a cancer-data reveal (per the news feed). One item is flagged RED under "RISK WATCH" describing a 6.1% drop amid sector-wide selling (per the news feed); the remaining items are flagged YELLOW under "MARKET WIRE." The news items contain no verified figures beyond their headlines, so their quantitative content cannot be confirmed. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals (per the Butterfly Supply-Chain Graph).

• What are the company's products, revenue sources, and customer base, given that FY 2025 revenue of $33.0M is reported without a business description?
• What is the company's current debt level, since the Debt field is N/A in every reported period while Debt/Equity is cited as 0.5?
• What is the terms and size of the stock offering referenced in news headlines, and how does it affect share count and dilution?
• What is the basis of the reported EPS, which is N/A in every period, and what are the trailing P/E and EV/EBITDA figures?
• What institutional (13F) and insider (Form 4) holdings exist, since the holders section contains no records?